Developer docs
API playgroundTry for free, no card

Search company profiles

Enodia Therapeutics

Full company profile

uuid00fufcy

Namestring
Enodia Therapeutics
Legal namestring
Enodia Therapeutics
Websiteurl
enodiatx.com
Company typeenum
Private
Founded yearint
2025
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, small molecule therapeutics, SEC61 translocon modulation, immuno-inflammatory drug discovery, preclinical biotechnology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Protein Degradation Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue biotech company developing small-molecule therapies for targeted protein degradation. Revenue generation anticipated through eventual pharmaceutical partnerships, licensing deals, and product commercialization following successful clinical development.

bioworld.com
2Asset Acquisition Payments
TypeLicensing Royalties
Description

Kezar Life Sciences receives $1 million upfront payment and up to $127 million in potential development, regulatory, and commercialization milestone payments, plus tiered royalties on net sales from the acquired Sec61 program.

enodiatx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enodia Therapeutics develops small-molecule therapies that selectively modulate the SEC61 translocon to degrade disease-driving secreted and transmembrane proteins at the point of synthesis, before they can cause damage. The company combines proprietary proteomics, machine learning, signal-peptide-informed cell line libraries, and Cryo-EM structural data to rationally design selective SEC61 inhibitors. Lead programs target inflammatory and autoimmune diseases, with pipeline expansion potential into oncology and viral infections, including the recently acquired clinical-stage candidate KZR-261 from Kezar Life Sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 95% of secreted proteins and 80% of transmembrane proteins can be targeted through Sec61 modulation
+1 more record
Product overview1 text field

Enodia Therapeutics is developing a unified SEC61 Translocon-Modulating Platform for targeted protein degradation at the point of synthesis. The platform integrates machine learning, proteomics-informed secretome analysis, and structural validation (Cryo-EM) to design selective small-molecule inhibitors. The company's pipeline includes lead programs for autoimmune and inflammatory diseases, with potential expansion into oncology and virology. The platform leverages an acquired clinical-stage asset (KZR-261) and extensive preclinical datasets from Kezar Life Sciences to strengthen the company's therapeutic offerings across inflammation, immunology, and oncology.

Product and service3 records
1SEC61 Translocon-Modulating Platform
CategoryDrug Discovery Platform
Description

Proprietary discovery platform that uses machine learning, proteomics-informed secretome analysis, signal-peptide cell line libraries, and Cryo-EM structural validation to selectively modulate the SEC61 translocon, enabling targeted protein degradation at the point of synthesis before disease-causing proteins are secreted. Used internally to generate SEC61 inhibitor candidates for inflammatory, autoimmune, oncological, and viral indications.

2Lead Programs for Autoimmune and Inflammatory Diseases
CategoryPreclinical Pipeline Program
Description

Two preclinical small-molecule SEC61 inhibitor drug candidates designed for inflammatory and autoimmune diseases, with potential applications extending into oncology and viral infections. Leverages the SEC61 Translocon-Modulating Platform and is being advanced toward preclinical candidate selection.

3KZR-261
CategoryClinical-Stage Acquired Asset
Description

Clinical-stage Sec61 inhibitor previously advanced by Kezar Life Sciences, which had initiated a Phase I trial in solid tumor patients in 2021 before terminating it. Acquired by Enodia Therapeutics to strengthen the SEC61 portfolio and accelerate development of small-molecule inhibitors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Enodia acquired Kezar's Sec61-based discovery and development program assets including preclinical datasets and the clinical-stage drug candidate KZR-261. Deal includes $1 million upfront payment and up to $127 million in potential milestone payments plus tiered royalties. Kezar spent nearly ten years pioneering Sec61 translocon research, which Enodia will advance.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Enodia originated from foundational research at Institut Pasteur led by Prof. Caroline Demangel, who discovered the mechanism of action of mycolactone (a natural Sec61 inhibitor). The company was built on science from Institut Pasteur's Immunobiology and Therapy Research Unit. Institut Pasteur is also an investor and board observer.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Argobio is the startup studio that selected, incubated, and built Enodia Therapeutics. The company was created by Argobio Studio and The Institut Pasteur. Argobio provides ongoing board representation and strategic support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enodia Therapeutics

Targeted Protein Degradation Therapeuticsenodiatx.com

Enodia Therapeutics firmographics

Firmographics
Name
Enodia Therapeutics
Legal name
Enodia Therapeutics
Website
https://enodiatx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Enodia Therapeutics is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Enodia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biotech company developing small-molecule therapies for targeted protein degradation. Revenue generation anticipated through eventual pharmaceutical partnerships, licensing deals, and product commercialization following successful clinical development.
  2. Asset Acquisition Payments: Kezar Life Sciences receives $1 million upfront payment and up to $127 million in potential development, regulatory, and commercialization milestone payments, plus tiered royalties on net sales from the acquired Sec61 program.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Enodia Therapeutics product offering

Product offering

Core offering

Enodia Therapeutics develops small-molecule therapies that selectively modulate the SEC61 translocon to degrade disease-driving secreted and transmembrane proteins at the point of synthesis, before they can cause damage. The company combines proprietary proteomics, machine learning, signal-peptide-informed cell line libraries, and Cryo-EM structural data to rationally design selective SEC61 inhibitors. Lead programs target inflammatory and autoimmune diseases, with pipeline expansion potential into oncology and viral infections, including the recently acquired clinical-stage candidate KZR-261 from Kezar Life Sciences.

Product overview

Enodia Therapeutics is developing a unified SEC61 Translocon-Modulating Platform for targeted protein degradation at the point of synthesis. The platform integrates machine learning, proteomics-informed secretome analysis, and structural validation (Cryo-EM) to design selective small-molecule inhibitors. The company's pipeline includes lead programs for autoimmune and inflammatory diseases, with potential expansion into oncology and virology. The platform leverages an acquired clinical-stage asset (KZR-261) and extensive preclinical datasets from Kezar Life Sciences to strengthen the company's therapeutic offerings across inflammation, immunology, and oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • SEC61 Translocon-Modulating Platform Proprietary discovery platform that uses machine learning, proteomics-informed secretome analysis, signal-peptide cell line libraries, and Cryo-EM structural validation to selectively modulate the SEC61 translocon, enabling targeted protein degradation at the point of synthesis before disease-causing proteins are secreted. Used internally to generate SEC61 inhibitor candidates for inflammatory, autoimmune, oncological, and viral indications.
  • Lead Programs for Autoimmune and Inflammatory Diseases Two preclinical small-molecule SEC61 inhibitor drug candidates designed for inflammatory and autoimmune diseases, with potential applications extending into oncology and viral infections. Leverages the SEC61 Translocon-Modulating Platform and is being advanced toward preclinical candidate selection.
  • KZR-261 Clinical-stage Sec61 inhibitor previously advanced by Kezar Life Sciences, which had initiated a Phase I trial in solid tumor patients in 2021 before terminating it. Acquired by Enodia Therapeutics to strengthen the SEC61 portfolio and accelerate development of small-molecule inhibitors.

Quantifiable outcome

  • 95% of secreted proteins and 80% of transmembrane proteins can be targeted through Sec61 modulation
  • +1 more outcomes

Companies that use Enodia Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Enodia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Enodia Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Kezar Life SciencescoreStrategic or Co-development Partner · 8 January 2026Enodia acquired Kezar's Sec61-based discovery and development program assets including preclinical datasets and the clinical-stage drug candidate KZR-261. Deal includes $1 million upfront payment and up to $127 million in potential milestone payments plus tiered royalties. Kezar spent nearly ten years pioneering Sec61 translocon research, which Enodia will advance.
  • Institut PasteurcoreStrategic or Co-development PartnerEnodia originated from foundational research at Institut Pasteur led by Prof. Caroline Demangel, who discovered the mechanism of action of mycolactone (a natural Sec61 inhibitor). The company was built on science from Institut Pasteur's Immunobiology and Therapy Research Unit. Institut Pasteur is also an investor and board observer.
  • Argobio StudiocoreStrategic or Co-development PartnerArgobio is the startup studio that selected, incubated, and built Enodia Therapeutics. The company was created by Argobio Studio and The Institut Pasteur. Argobio provides ongoing board representation and strategic support.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Enodia Therapeutics competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat3 records

Customer concentration

Enodia Therapeutics social profiles

Digital presence

Enodia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enodia Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Enodia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enodia Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enodia Therapeutics

What does Enodia Therapeutics do?

Enodia Therapeutics develops small-molecule therapies that selectively modulate the SEC61 translocon to degrade disease-driving secreted and transmembrane proteins at the point of synthesis, before they can cause damage. The company combines proprietary proteomics, machine learning, signal-peptide-informed cell line libraries, and Cryo-EM structural data to rationally design selective SEC61 inhibitors. Lead programs target inflammatory and autoimmune diseases, with pipeline expansion potential into oncology and viral infections, including the recently acquired clinical-stage candidate KZR-261 from Kezar Life Sciences.

Is Enodia Therapeutics a public or private company?

Enodia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Enodia Therapeutics founded?

Enodia Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is Enodia Therapeutics based?

Enodia Therapeutics is headquartered in Paris, France, in the Europe region.

How does Enodia Therapeutics make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are asset Acquisition Payments.

Does Enodia Therapeutics have an API?

No public API is recorded for Enodia Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileEnodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic DevelopmentEnodia Therapeutics appointed Henrik Torp Nielsen as Chief Financial Officer, bringing nearly two decades of biopharma finance experience. He will lead financial strategy as the company advances its Sec61 platform targeting disease-driving proteins, with initial focus on inflammatory and autoimmune diseases and oncology opportunities.AktienEnodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic DevelopmentEnodia Therapeutics appointed Henrik Torp Nielsen as Chief Financial Officer, bringing nearly two decades of biopharma finance experience. He will lead financial strategy as the company advances its Sec61 platform targeting disease-driving proteins, with initial focus on inflammatory and autoimmune diseases and oncology opportunities.FinancialContent Business PageEnodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic DevelopmentEnodia Therapeutics appointed Henrik Torp Nielsen as Chief Financial Officer, bringing nearly two decades of biopharma finance experience. He will lead financial strategy and operations as the company advances its Sec61 platform targeting inflammatory, autoimmune, and oncology diseases.Pharmaceutical TechnologyPfizer partners with Enodia Therapeutics in $500m drug dealPfizer and Enodia Therapeutics announced a research collaboration and licensing deal potentially worth over $500m to develop Sec61 inhibitors. Enodia will handle initial discovery, while Pfizer takes over clinical trials and commercialization. The partnership targets immunology, oncology, and inflammation.GenengnewsEnodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small MoleculesEnodia Therapeutics and Pfizer announced a collaboration to develop Sec61-targeting small molecules, with Pfizer handling clinical and commercial activities. Enodia will receive an upfront payment and milestone royalties, with total potential value exceeding $500 million. The deal follows Enodia's acquisition of Kezar Life Sciences' Sec61 assets.Business Wire BlogEnodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small MoleculesEnodia Therapeutics announced a research collaboration and license agreement with Pfizer to develop Sec61 inhibitors. Enodia will conduct discovery, and Pfizer will handle clinical and commercial activities after the term. The deal includes an upfront payment and potential milestone and royalty payments totaling over $500 million.FinancialContent Business PageEnodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small MoleculesEnodia Therapeutics announced a research collaboration and license agreement with Pfizer to develop Sec61 inhibitors. Enodia will conduct discovery, with Pfizer handling clinical and commercial activities after the term. The deal includes an upfront payment and potential milestones and royalties totaling over $500 million.STATUp and down the ladder: The latest comings and goingsEnodia Therapeutics hired Yvonne McGrath as chief scientific officer, a role she previously held at iTeos Therapeutics. The company's hiring move is highlighted in a weekly feature, with no further details provided.The Pharma LetterYvonne McGrath named CSO at EnodiaEnodia Therapeutics appointed Yvonne McGrath as chief scientific officer. She brings over 25 years of biopharma drug development experience to help optimize the company's proprietary platform.BioSpaceEnodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation PlatformEnodia Therapeutics appointed Dr. Yvonne McGrath as Chief Scientific Officer to accelerate its upstream targeted protein degradation platform. McGrath brings over 25 years of biopharma experience, including prior roles at iTeos Therapeutics, Complix, and Immunocore. She will help optimize the company's Sec61-based small-molecule therapies.